Stablecoin Development Corporation · AMEX:SDEV

Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (September 2016)

26 slides from Stablecoin Development's investor presentation, September 2016

  1. Slide 1: NovaBay Pharmaceuticals

    NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market September 2016 NYSE MKT: NBY www.novabay.com

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”

  3. Slide 3: Strategic Focus on Eye Care

    Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa

  4. Slide 4: The Foundation of NovaBay's Technology

    The Foundation of NovaBay’s Technology White Blood Cell in Action Invading Microbe White Blood Cell Red Blood Cells Neutrox™ NovaBay’s proprietary, pure Hypochlorous Acid solution 4

  5. Slide 5: Does not generate resistance; removal; anti-biofilm

    Does not ✓ generate Resistance ✓ Removal Bacterial ✓ Mechanical Debridement ✓ Anti-biofilm Activity ✓ Anti-Toxin 5

  6. Slide 6: 41 Million Potential Patients in U.S.

    41 Million Potential Patients in U.S. 6

  7. Slide 7: What is Blepharitis?

    What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease  Signs and symptoms ‒ Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation  High incidence ‒ 37% of patients seen by ophthalmologists ‒ 47% of patients seen by optometrists  Most common cause is st

  8. Slide 8: Case Study – Compelling Results with Avenova

    Case Study – Compelling Results with 8

  9. Slide 9: Only two Ingredients = Pure Hypochlorous Acid + Saline

    Only two Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Water , PEG-80 Sorbitan Water , PEG 80 , Sorbitan Water, Poloxamer, non-foaming Water, Water USP Laurate , Sodium Laurate , Sodium Polyethylene, pH balanced Cocamidopropyl

  10. Slide 10: Growing Commercial Presence

    Growing Commercial Presence 10

  11. Slide 11: Avenova Daily Lid & Lash Hygiene

    mm a Avenova’ |} Daily Lid & Lash Hygiene “Neutrox N®vaBay

  12. Slide 12: Addressing Major U.S. Markets

    Addressing Major U.S. Markets 12

  13. Slide 13: Market Coverage

    Market Coverage 43 Direct Medical Reps In Key Metro Areas Northeast (11): Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago-No, Chicago-So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel

  14. Slide 14: Net Sales ($000)

    2,578 Net Sales ($000) Prescriptions 1,664 Direct Buy & Bill Sales 1,580 1,366 465 1,118 553 321 806 122 465 797 1,115 40 684 914 813 425 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016

  15. Slide 15: Driving Toward Operating Cash-Flow Breakeven in 2016

    15 Driving Toward Operating Cash-Flow Breakeven in 2016 Combination of Growing Avenova Sales, GPM and Cost Reductions 500 - Breakeven (500) (1,000) (1,500) (2,000) (2,441) (2,500) (2,843) (2,982) (3,000) (3,487) (3,500) (3,786) (4,150) (4,078) (4,113) (4,000) (4,661) (4,624) (4,500) (4,867) (4,859)

  16. Slide 16: Avenova Phased Commercial Strategy

    Avenova Phased Commercial Strategy 16

  17. Slide 17: Avenova Phased Commercial Strategy

    Avenova Phased Commercial Strategy  Phase 1 – Initial Launch ‒ 2015 launch targeted two sales channels at introductory pricing 1. Sales Reps detailing directly to MD’s and OD’s - Primary emphasis - Most efficient approach to seed the market 2. Prescription sales - Once doctors comfortable with prod

  18. Slide 18: Reimbursement

    Reimbursement Insurance Coverage Continues to Grow  Insurance plan coverage nearly tripled from 34% to >90% in 2016  Coverage essential to implement value pricing model 18

  19. Slide 19: Key Opinion Leader Endorsements

    Key Opinion Leader Endorsements 19

  20. Slide 20: KOL from Across U.S. Support

    KOL from Across U.S. Support Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chap

  21. Slide 21: KOLs from Across U.S. Support

    KOLs from Across U.S. Support Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry-Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally r

  22. Slide 22: Advertising and Collateral Marketing Materials

    Advertising Placements in Top Trade Journals Collateral Marketing Materials 22 22

  23. Slide 23: Interactive Website

    Interactive Website Find a Physician Find a Pharmacy 23

  24. Slide 24: Financial Overview

    Financial Overview Million Market Cap (8/16/16) $44 Cash (6/30/16) $3.5 (Excludes $4 million Financing proceeds received in July) Debt $0 Shares Outstanding 11 (Excludes 4.5M Warrants and 1.5M Stock Options)

  25. Slide 25: Strategic Focus on Eye Care

    Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa

  26. Slide 26: NovaBay Pharmaceuticals

    NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market NYSE MKT: NBY www.novabay.com August, 2016

NovaBay Pharmaceuticals — Investor Presentation (September 2016) on 6ix